It was a pleasure to speak to Christopher Cannon to discuss the much-anticipated results of the VERTIS-CV trial (ClinicalTrials.gov Identifier: NCT01986881) evaluating the efficacy and safety and cardiovascular outcomes of ertugliflozin in type 2 diabetes.
1. Could you tell us a little about the VERTIS-CV trial and its primary and secondary outcome data? (0:06)
2. What were the major safety findings, including the effects on diabetic ketoacidosis and acute kidney injury? (2:44)
3. How do these compare to data from the other SGLT2 cardiovascular outcome trials? (3:50)
4. Why do you think this study has not shown a statistically significant effect on reducing the incidence of CV disease death and heart failure hospitalisations? (4:42)
5. With an increasing number of SGLT inhibitors available, what factors should be considered in choosing between them? (6:18)
Speaker disclosure: Christopher Cannon has received research grants from Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck and Pfizer and consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Sanofi and Rhoshan.
Support: Interview commissioned and filming supported by Touch Medical Media.
Filmed in coverage of the ADA 2020 Virtual 80th Scientific Sessions.
Share this Video
Related Videos In Diabetes
Juliana Chan, EASD 2020 – COVID-19 and type 1 diabetes
We spoke with Prof. Juliana Chan (The Chinese University of Hong Kong, Hong Kong) following her session on COVID-19 and the impact on patients with type 1 diabetes. Questions What key areas of diabetes and COVID-19 were discussed at EASD 2020? (0:05) How do you think the COVID-19 pandemic has affected treatment both now and […]
Tina Vilsbøll, EASD 2020 – Oral GLP-1RA therapy and individualized care
We were delighted to speak with Prof. Tina Vilsbøll (University of Copenhagen, Copenhagen, Denmark) about the approval of semaglutide and the impact on the GLP-1RA landscape, and the movement towards individualizing care in patients with type 2 diabetes. Questions What has been the impact of the approval of oral semaglutide in the GLP-1RA landscape? (0:15) […]
Gian Paolo Fadini, EASD 2020 – Highlights from EASD 2020
We were delighted to speak with Dr Gian Paolo Fadini (University of Padova, Venetian Institute of Molecular Medicine, Padova, Italy) about his highlights from the virtual EASD 2020 meeting. Disclosures: Dr Gian Paolo Fadini has received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp and Dohme, Mundipharma, Novartis Novo Nordisk, Sanofi […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!